Compare Anheuser-Busch Inbev SA (BUD) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Cytokinetics Inc — how do they compare? Anheuser-Busch Inbev SA trades at $80.24 (market cap $163.79B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Anheuser-Busch Inbev SA is far larger — about 15.2× Cytokinetics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.62% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BUD | CYTK | |
|---|---|---|
Market Cap | $163.79B | $10.78B |
Sector | Consumer Staples | Technology |
52-Week High | $86.48 | $87.26 |
52-Week Low | $57.93 | $34.31 |
Enterprise Value | $228.20B | $10.88B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.76, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $90.17. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 expected, while revenue trends show modest growth, and net income margin improved to 11.52% in 2025. Cash flow remains positive, and debt-to-asset ratios have declined steadily since 2021.
The outlook is positive given strong analyst buy ratings (57.78%) and projected earnings growth, but risks include competitive pressures and macroeconomic sensitivity. The stock offers value with a P/E of 18.05 and stable profitability, though investor sentiment is mixed amid recent institutional selling and news of a major shareholder divestment.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
